Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

101.88 -0.44 (-0.43%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,181,010
Open 101.78
Bid (Size) 101.90 (2)
Ask (Size) 102.32 (1)
Prev. Close 102.32
Today's Range 101.21 - 102.72
52wk Range 98.60 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.87%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 Dividend Stocks to Buy for a Lifetime of Passive Income
These are the kinds of stocks that can allow investors to sleep easy at night. 
Via The Motley Fool
Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with Winrevair showing promising performance. 
Via Benzinga

Performance

YTD
-10.03%
-10.03%
1 Month
-7.53%
-7.53%
3 Month
-9.29%
-9.29%
6 Month
-20.14%
-20.14%
1 Year
-1.45%
-1.45%

More News

Read More
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
Is Merck Stock a Buy?
Via The Motley Fool
NYSE:MRK stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
A Look Into Merck & Co Inc's Price Over Earnings
Via Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Via Benzinga
Merck (MRK) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Merck Q3 Earnings And Revenues Top Estimates
Via Talk Markets
Where Will Merck Be in 5 Years?
Via The Motley Fool
(MRK) - Analyzing Merck & Co's Short Interest
Via Benzinga
Merck Beats Q3 Estimates, But Lowers Annual Forecast As Gardasil Vaccine Hit By Low China Demand
Via Benzinga
Will Merck's Guidance Cut Prove Gruesome In The Wake Of Januvia, Gardasil Misses?
Via Investor's Business Daily
3 Dividend Stocks That Could Raise Their Payouts in November
Via The Motley Fool
Merck Announces Third-Quarter 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
Why Is Moderna Stock Trading Higher On Monday?
Via Benzinga
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
What Lies In Store For Healthcare ETFs In Q3 Earnings?
Via Talk Markets
Topics ETFs
Pfizer, Live Nation Entertainment And More On CNBC's 'Final Trades'
Via Benzinga
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
Via Benzinga
3 Absurdly Cheap Stocks That Pay High Dividends
Via The Motley Fool
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers
From Merck & Co., Inc.
Via Business Wire
CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older
From Merck & Co., Inc.
Via Business Wire
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
Via Benzinga
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.